^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Merkel Cell Carcinoma

    Related cancers:
    6d
    CXorf67 in malignancies: Deciphering epigenetic landscapes and clinical implications for precision oncology. (PubMed, Genes Dis)
    However, further research is needed to explore its functions in other cancers and clarify its molecular mechanisms. Our review synthesizes current knowledge on CXorf67's biological significance, particularly in epigenetics and DNA damage, and its implications in oncogenesis.
    Review • Journal
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PALB2 (Partner and localizer of BRCA2) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
    9d
    Coexistence of Hyalinizing Trabecular Tumor and Papillary Thyroid Carcinoma: A Diagnostic Challenge. (PubMed, AACE Endocrinol Diabetes)
    This case underscores the importance of integrating cytologic, histopathologic, and molecular features when evaluating thyroid nodules with overlapping characteristics. Recognition of this rare coexistence prevents misclassification and unnecessary aggressive management, ensuring accurate diagnosis and optimal patient outcomes.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • KRT19 (Keratin 19)
    11d
    Degradation-Controlled Synchronization of HIF-2α and MEK Inhibition Using Self-Sealed Porous Silicon Nanoparticles to Reprogram Tumor Immunogenicity. (PubMed, Acta Biomater)
    In contrast, degradation-governed release from PSiNPs sustained the availability of belzutifan and trametinib in aqueous physiological medium for more than 10 days supporting prolonged intracellular drug exposure when combined with the established cellular internalization of this carrier system. Sustained dual inhibition enhanced cytotoxicity and promoted immunogenic remodeling in MCPyV-negative Merkel cell carcinoma models, including increased calreticulin exposure and reduced PD-L1 expression. These findings identify release synchronization as a critical biomaterial design parameter for combination cancer therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • EPAS1 (Endothelial PAS domain protein 1) • CALR (Calreticulin)
    |
    PD-L1 expression
    |
    Mekinist (trametinib) • Welireg (belzutifan)
    12d
    Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers (clinicaltrials.gov)
    P=N/A, N=20, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
    Enrollment closed
    14d
    Merkel Cell Polyomavirus and DNA Damage Response (DDR): Transcriptional Analysis of DDR Pathways in the Context of Merkel Cell Carcinoma. (PubMed, Cancers (Basel))
    Our findings support the role of MCPyV in MCC formation and suggest its involvement in the transcriptional regulation of DDR genes, which may influence tumor progression. Understanding the molecular interplay between MCPyV and the DDR may guide future research into plausible novel diagnostic and therapeutic strategies for virus-induced tumors.
    Journal
    |
    CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • CHEK1 (Checkpoint kinase 1) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    14d
    Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=36, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Recruiting
    Enrollment open
    |
    CD4 (CD4 Molecule)
    |
    Libtayo (cemiplimab-rwlc)
    15d
    Vulvar small cell neuroendocrine carcinoma arising from differentiated vulvar intraepithelial neoplasia: evidence of a clonal relationship by mutation analysis. (PubMed, Virchows Arch)
    HPV testing was negative. These findings support the hypothesis of stepwise tumor progression from a squamous precursor with RB1 and TP53 alterations, suggesting a mechanism for neuroendocrine transdifferentiation.
    Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1)
    |
    TP53 mutation
    19d
    CARADERM: French National Database of Rare Dermatological Cancers (clinicaltrials.gov)
    P=N/A, N=9000, Recruiting, University Hospital, Lille | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    24d
    Role of POU4F3 in the Diagnosis of Cutaneous Follicular Tumors. (PubMed, J Cutan Pathol)
    These findings support POU4F3's diagnostic value in distinguishing benign follicular tumors from malignant histopathologic mimics.
    Journal
    |
    KRT20 (Keratin 20) • POU4F3 (POU Class 4 Homeobox 3)
    29d
    DOTATOC PET/CT for Imaging NET Patients (clinicaltrials.gov)
    P=N/A, N=800, Active, not recruiting, British Columbia Cancer Agency | Trial primary completion date: Sep 2025 --> Sep 2026
    Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    29d
    Alliance A091605: Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma (clinicaltrials.gov)
    P2, N=9, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2026 --> Feb 2026
    Trial completion • Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab)
    1m
    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)